Release Date: 29/05/19 09:45 Summary: Strategic Review Outcome and Program Updates Price Sensitive: Yes Download Document 106.63KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%